Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study
NCT07925398, Phase 3, Not yet recruiting, Zhongda Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Hetrombopag for Thrombocytopenia in Patients Scheduled for Elective Hepatic Interventional Diagnostic and Therapeutic Procedures: A Clinical Study | ClinicalTrials.gov |
| NCT number | NCT07925398 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 3 | ClinicalTrials.gov |
| Enrollment | 108 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Zhongda Hospital | ClinicalTrials.gov |
| Conditions | Thrombocytopenia, Hepatic Interventional Procedure | ClinicalTrials.gov |
| Interventions | Hetrombopag, Placebo | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | The proportion of participants with PLT ≥50×10⁹/L at 24 hours preoperatively and no rescue bleeding treatment within 7 days postoperatively. | Perioperative, up to postoperative Day 7 | The primary endpoint is the percentage of subjects who achieve platelet count ≥50×10⁹/L within 24 hours before operation and do not receive rescue treatment for bleeding during the first 7 days after surgery. | ClinicalTrials.gov |
| Secondary | The proportion of participants with PLT ≥50×10⁹/L at 24 hours preoperatively. | Within 24 hours before surgery | The percentage of subjects whose platelet count reaches ≥50×10⁹/L within 24 hours before surgery. | ClinicalTrials.gov |
| Secondary | The proportion of participants with an increase in PLT ≥20×10⁹/L from baseline at 24 hours preoperatively. | Baseline and within 24 hours before surge | The percentage of subjects with platelet count elevation of at least 20×10⁹/L compared with baseline at 24 hours before surgery. | ClinicalTrials.gov |
| Secondary | The proportion of participants without platelet transfusion during the study period. | Through study completion, an average of 35 days | The percentage of subjects who do not receive any platelet transfusion throughout the study. | ClinicalTrials.gov |
| Secondary | Duration of platelet count maintaining PLT ≥50×10⁹/L. | Through study completion, an average of 35 days | The length of time that platelet count remains at or above 50×10⁹/L. | ClinicalTrials.gov |
| Secondary | Change in platelet count at different visit time points. | Baseline and at all scheduled study visits through study completion, an average of 35 days | The change from baseline in platelet count assessed at each scheduled study visit. | ClinicalTrials.gov |
| Secondary | The proportion of participants without delay, cancellation or discontinuation of systemic anti-tumor therapy due to thrombocytopenia. | Through study completion, an average of 35 days | The percentage of subjects whose systemic anti-tumor therapy is not delayed, cancelled or discontinued because of thrombocytopenia. | ClinicalTrials.gov |
| Secondary | The proportion of participants requiring rescue treatment for bleeding. | Through study completion, an average of 35 days | The percentage of subjects who receive rescue therapy for bleeding events. | ClinicalTrials.gov |
| Secondary | Number and dose of platelet transfusions. | Through study completion, an average of 35 days | The total number and administered dose of platelet transfusions received by subjects during the study. | ClinicalTrials.gov |
| Secondary | Number of participants with at least one treatment-related adverse event, clinically significant laboratory abnormality or vital sign abnormality assessed by CTCAE v5.0 | Through study completion, an average of 35 days | The count of subjects who develop at least one treatment-related adverse event, clinically significant laboratory abnormality or abnormal vital sign. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)